Kim Byung-Gun, Kim Hyunzu, Lim Hyun-Kyoung, Yang Chunwoo, Oh Sora, Lee Byung-Wook
Department of Anesthesiology and Pain Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.
Korean J Anesthesiol. 2017 Oct;70(5):520-526. doi: 10.4097/kjae.2017.70.5.520. Epub 2017 Apr 28.
Postoperative nausea and vomiting (PONV) is one of the major concerns after anesthesia and surgery, and it may be more frequent in orthopedic patients receiving patient-controlled epidural analgesia (PCEA). The purpose of this study was to compare the effect of palonosetron and dexamethasone on the prevention of PONV in patients undergoing total joint arthroplasty and receiving PCEA.
Patients scheduled for total hip or knee arthroplasty under spinal anesthesia/PCEA were randomly allocated to receive either intravenous palonosetron (0.075 mg, n = 50) or dexamethasone (5 mg, n = 50). Treatments were administered intravenously to the patients 30 min before the beginning of surgery. The total incidence of PONV and incidence in each time period, severity of nausea, need for rescue anti-emetics, pain score, and adverse effects during the first 48 h postoperatively were evaluated.
The total incidence of PONV was lower in the palonosetron group compared with the dexamethasone group (18.4% vs. 36.7%, P = 0.042), but there were no statistically significant differences in incidence between the groups at all time points. No significant intergroup differences were observed in the severity of nausea, use of rescue anti-emetics, pain score, and adverse effects.
Although there were no significant differences in the incidence of PONV between the treatment groups at all time points, intravenous palonosetron reduced the total incidence of PONV in orthopedic patients receiving PCEA compared with dexamethasone.
术后恶心呕吐(PONV)是麻醉和手术后的主要问题之一,在接受患者自控硬膜外镇痛(PCEA)的骨科患者中可能更常见。本研究的目的是比较帕洛诺司琼和地塞米松对接受全关节置换术并接受PCEA的患者预防PONV的效果。
计划在脊髓麻醉/PCEA下进行全髋关节或膝关节置换术的患者被随机分配接受静脉注射帕洛诺司琼(0.075mg,n = 50)或地塞米松(5mg,n = 50)。在手术开始前30分钟对患者进行静脉给药。评估术后48小时内PONV的总发生率、各时间段的发生率、恶心严重程度、使用急救止吐药的需求、疼痛评分和不良反应。
帕洛诺司琼组的PONV总发生率低于地塞米松组(18.4%对36.7%,P = 0.042),但两组在所有时间点的发生率无统计学显著差异。在恶心严重程度、使用急救止吐药、疼痛评分和不良反应方面,未观察到组间有显著差异。
尽管各治疗组在所有时间点的PONV发生率无显著差异,但与地塞米松相比,静脉注射帕洛诺司琼降低了接受PCEA的骨科患者的PONV总发生率。